Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection

NCT04408183 is registered in ClinicalTrials.gov with GeneOne Life Science, Inc. as lead sponsor.

NCT NCT04408183
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04408183 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy, Safety, and Tolerability of GLS-1200 Topical Nasal Spray in the Prevention of Incident Confirmed, Symptomatic SARS-CoV-2 Infection
Lead sponsor
GeneOne Life Science, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 10, 2020
Completion date
January 10, 2023
Enrollment
184 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

infection, sars-cov 2